NEW TAIPEI CITY, Taiwan, May 18, 2026
Caliway Biopharmaceuticals unveiled new preclinical findings at the European Congress on Obesity 2026 (ECO 2026) demonstrating that its investigational fat-reduction therapy CBL-514, when combined with leading GLP-1 receptor-based weight-loss drugs, significantly enhanced weight reduction, reduced fat accumulation, improved post-treatment weight maintenance, and showed promising metabolic benefits in animal studies. The oral presentation attracted strong attention from international obesity experts, clinicians, and multinational pharmaceutical companies, highlighting growing industry interest in next-generation obesity combination therapies.
CBL-514 Combination Therapy Boosts Weight Loss Outcomes
The presentation, delivered by internationally recognized obesity medicine expert Dr. Arya M. Sharma, focused on preclinical studies evaluating CBL-514 in combination with semaglutide and tirzepatide, two major GLP-1 receptor-based obesity therapies rapidly transforming the global weight-loss market.
According to the presented data, combining CBL-514 with semaglutide resulted in a 91.5% greater reduction in body weight compared with semaglutide monotherapy alone in animal models. Researchers also observed significant improvements in body composition, including stronger reductions in both subcutaneous fat and visceral fat, two major contributors to obesity-related metabolic disorders.
In studies involving tirzepatide, animals receiving the monotherapy experienced 55.9% weight regain after treatment discontinuation, while the CBL-514 combination group showed only 25.2% weight regain, suggesting the therapy may improve long-term weight maintenance following GLP-1 treatment.
Researchers reported that the combination further reduced subcutaneous fat by 182.5% and visceral fat by 367.4% compared with GLP-1 therapy alone, supporting the potential of CBL-514 to optimize body contouring and metabolic outcomes after weight reduction.
Advertisement
First International Presentation of Liver Metabolic Benefits
The ECO 2026 oral presentation also marked the first international disclosure of CBL-514’s potential impact on liver metabolic health. Researchers observed significant improvements in hepatic metabolic indicators when CBL-514 was combined with semaglutide.
Compared with control groups, the combination therapy reduced hepatic lipid content by 40.4% and hepatic cholesterol by 52.7%. Improvements were also observed in liver inflammation markers and histopathological indicators associated with non-alcoholic fatty liver disease (NAFLD), including steatosis and NAS scores.
These findings suggest CBL-514 may have future applications beyond aesthetic fat reduction, potentially expanding into broader obesity and metabolic disease management markets. Industry analysts increasingly view obesity therapies that improve both weight loss and metabolic health as the next major evolution within the rapidly growing GLP-1 treatment sector.
Strong Interest From Global Pharmaceutical Companies
Caliway stated that the ECO 2026 presentation drew more than 300 attendees, including obesity specialists, clinicians, academic researchers, and senior representatives from multinational pharmaceutical companies. The company reported strong post-presentation engagement and discussions with global industry leaders regarding the future potential of CBL-514 in obesity and metabolic medicine.
Laura Chung, Vice President of Caliway, noted that while GLP-1 therapies have dramatically reshaped the weight-loss market, the next major challenge is helping patients maintain healthier body composition and metabolic outcomes after significant weight reduction. She emphasized that CBL-514’s differentiated mechanism could position the therapy as a valuable complementary treatment in future obesity management strategies.
CBL-514 is a first-in-class injectable small-molecule therapy designed to induce adipocyte apoptosis, selectively eliminating fat cells without surgery. The therapy has completed 10 clinical trials involving 544 subjects, with all primary safety and efficacy endpoints reportedly achieved.
Caliway also confirmed that additional preclinical data involving CBL-514 combinations with GLP-1 therapies have been selected for presentation at the American Diabetes Association 2026 Scientific Sessions in June. The company plans to continue advancing human clinical studies and expanding global licensing discussions for the therapy.
Source: Caliway Biopharmaceuticals press release
